Tesamorelin

FOR LABORATORY AND INVESTIGATIONAL RESEARCH ONLY. Not approved for human or veterinary therapeutic use. Not for clinical applications. Not for human or animal consumption.

Tesamorelin preferentially reduces the visceral adipose tissue (VAT). GH release because of tesamorelin activates the hormone-sensitive lipase and adipose triglyceride lipase and suppresses the lipoprotein lipase activity to shift the adipocyte metabolism towards the triglyceride mobilization. [3]

VAT deposits are more sensitive to GH because of their depot-specific receptor density, vascular supply, and adipokine signaling. The selective lipolysis of tesamorelin in which reduces the VAT and relatively preserves the subcutaneous fat, improves the body composition and metabolic markers such as triglycerides and non-HDL cholesterol.

THIRD PARTY VERIFIED: Batch PLRXTS5928